The therapeutic potential of targeting the CHD protein family in cancer

被引：1
作者：
Zhang, Min [1 ]
Wu, Kaiyuan [5 ,7 ,8 ]
Zhang, Weijie [2 ,3 ]
Lin, Xia [1 ]
Cao, Qi [4 ]
Zhang, Lili [5 ,6 ]
Chen, Kaifu [5 ,6 ,7 ,9 ]
机构：
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Zhejiang Prov Key Lab Pancreat Dis, Hangzhou 310058, Zhejiang, Peoples R China
[2] Zhejiang Univ, Life Sci Inst, Zhejiang Prov Key Lab Canc Mol Cell Biol, Hangzhou 310058, Zhejiang, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Orthopaed Surg, Hangzhou 310058, Zhejiang, Peoples R China
[4] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA
[5] Boston Childrens Hosp, Dept Cardiol, Basic & Translat Res Div, Boston, MA 02115 USA
[6] Harvard Univ, Dana Farber & Harvard Canc Ctr, Prostate Canc Program, Boston, MA 02115 USA
[7] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA
[8] Rice Univ, Dept Bioengn, Houston, TX 77005 USA
[9] 300 Longwood Ave, Mailstop BCH3109, Boston, MA 02115 USA
来源：
PHARMACOLOGY & THERAPEUTICS | 2024年 / 256卷
关键词：
Epigenetic regulation; Cancer development; Chromatin remodeling; Therapeutic strategies; DNA METHYLTRANSFERASE INHIBITORS; AURORA-B; PROSTATE-CANCER; CELL-PROLIFERATION; DAMAGE RESPONSE; BREAST-CANCER; CHROMATIN; EZH2; BINDING; TRANSCRIPTION;
D O I：
10.1016/j.pharmthera.2024.108610
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Accumulating evidence indicates that epigenetic events undergo deregulation in various cancer types, playing crucial roles in tumor development. Among the epigenetic factors involved in the epigenetic remodeling of chromatin, the chromodomain helicase DNA-binding protein (CHD) family frequently exhibits gain- or loss-offunction mutations in distinct cancer types. Therefore, targeting CHD remodelers holds the potential for antitumor treatment. In this review, we discuss epigenetic regulations of cancer development. We emphasize proteins in the CHD family, delving deeply into the intricate mechanisms governing their functions. Additionally, we provide an overview of current therapeutic strategies targeting CHD family members in preclinical trials. We further discuss the promising approaches that have demonstrated early signs of success in cancer treatment. (c) 2024 Elsevier Inc. All rights reserved.
引用
收藏
页数：10
相关论文
共 109 条
  • [1] Acute loss of TET function results in aggressive myeloid cancer in mice
    An, Jungeun
    Gonzalez-Avalos, Edahi
    Chawla, Ashu
    Jeong, Mira
    Lopez-Moyado, Isaac F.
    Li, Wei
    Goodell, Margaret A.
    Chavez, Lukas
    Ko, Myunggon
    Rao, Anjana
    [J]. NATURE COMMUNICATIONS, 2015, 6
  • [2] Augello MA, 2019, CANCER CELL, V35, P603, DOI [10.1016/j.ccell.2019.03.001, 10.1016/j.ccell.2019.04.012]
  • [3] Structure and regulation of the human INO80-nucleosome complex
    Ayala, Rafael
    Willhoft, Oliver
    Aramayo, Ricardo J.
    Wilkinson, Martin
    McCormack, Elizabeth A.
    Ocloo, Lorraine
    Wigley, Dale B.
    Zhang, Xiaodong
    [J]. NATURE, 2018, 556 (7701) : 391 - +
  • [4] EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast
    Bachmann, IM
    Halvorsen, OJ
    Collett, K
    Stefansson, IM
    Straume, O
    Haukaas, SA
    Salvesen, HB
    Otte, AP
    Akslen, LA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (02) : 268 - 273
  • [5] Convergence of BMI1 and CHD7 on ERK Signaling in Medulloblastoma
    Badodi, Sara
    Dubuc, Adrian
    Zhang, Xinyu
    Rosser, Gabriel
    Jaeger, Mariane Da Cunha
    Kameda-Smith, Michelle M.
    Morrissy, Anca Sorana
    Guilhamon, Paul
    Suetterlin, Philipp
    Li, Xiao-Nan
    Guglielmi, Loredana
    Merve, Ashirwad
    Farooq, Hamza
    Lupien, Mathieu
    Singh, Sheila K.
    Basson, M. Albert
    Taylor, Michael D.
    Marino, Silvia
    [J]. CELL REPORTS, 2017, 21 (10): : 2772 - 2784
  • [6] Mammalian ISWI and SWI/SNF selectively mediate binding of distinct transcription factors
    Barisic, Darko
    Stadler, Michael B.
    Iurlaro, Mario
    Schuebeler, Dirk
    [J]. NATURE, 2019, 569 (7754) : 136 - +
  • [7] RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?
    Bobbin, Maggie L.
    Rossi, John J.
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 56, 2016, 56 : 103 - 122
  • [8] The SANT domain: a unique histone-tail-binding module?
    Boyer, LA
    Latek, RR
    Peterson, CL
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2004, 5 (02) : 158 - 163
  • [9] SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
    Boysen, Gunther
    Rodrigues, Daniel N.
    Rescigno, Pasquale
    Seed, George
    Dolling, David
    Riisnaes, Ruth
    Crespo, Mateus
    Zafeiriou, Zafeiris
    Sumanasuriya, Semini
    Bianchini, Diletta
    Hunt, Joanne
    Moloney, Deirdre
    Perez-Lopez, Raquel
    Tunariu, Nina
    Miranda, Susana
    Figueiredo, Ines
    Ferreira, Ana
    Christova, Rossitza
    Gil, Veronica
    Aziz, Sara
    Bertan, Claudia
    de Oliveira, Flavia M.
    Atkin, Mark
    Clarke, Matthew
    Goodall, Jane
    Sharp, Adam
    MacDonald, Theresa
    Rubin, Mark A.
    Yuan, Wei
    Barbieri, Christopher E.
    Carreira, Suzanne
    Mateo, Joaquin
    de Bono, Johann S.
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (22) : 5585 - 5593
  • [10] CHD1 Is a 5q21 Tumor Suppressor Required for ERG Rearrangement in Prostate Cancer
    Burkhardt, Lia
    Fuchs, Sarah
    Krohn, Antje
    Masser, Sawinee
    Mader, Malte
    Kluth, Martina
    Bachmann, Frederik
    Huland, Hartwig
    Steuber, Thomas
    Graefen, Markus
    Schlomm, Thorsten
    Minner, Sarah
    Sauter, Guido
    Sirma, Hueseyin
    Simon, Ronald
    [J]. CANCER RESEARCH, 2013, 73 (09) : 2795 - 2805
12345678910